Product details
Mazdutide (development codes IBI362 / LY3305677) is an investigational dual GLP-1 and glucagon receptor agonist. Within the incretin reference series it occupies a specific niche: it engages the GLP-1 and glucagon arms without the GIP component carried by Tirzepatide, and without the third (GIP) arm of the tri-agonist Retatrutide — which makes it the standard tool when a study needs the GLP-1 + glucagon combination isolated from GIP signalling. As an investigational compound it is not an approved finished drug; the material supplied here is a research reagent only.
Peptuno characterizes each Mazdutide lot as an analytical reference standard. The packet covers RP-HPLC purity (gradient method, UV 214 nm), ESI-MS for identity, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer; tandem-MS sequence verification is recommended at first-time qualification because dual-agonist sequences in this family are close enough that intact mass alone leaves identity ambiguity. The commonly cited CAS should be confirmed against the lot COA for the supplied form. Fills run mg-scale for reproducible aliquoting; this is reference-grade research material, distinct from compounding-scale API supply.
Regulatory note: Investigational compound in clinical development; not approved as a finished drug at the time of writing. Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations — not a finished dosage form and not labelled for human administration. CAS is commonly cited but should be verified per batch COA. Buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
FAQ
- Where does Mazdutide sit in the incretin receptor-coverage series?
- Receptor coverage is the axis that separates this family: Tirzepatide is GIP + GLP-1, Mazdutide is GLP-1 + glucagon, Retatrutide is GIP + GLP-1 + glucagon. Mazdutide is therefore the reference point for the GLP-1 + glucagon pair studied without a GIP arm. Peptuno supplies each member as an independently characterized lot, so a lab building a receptor-pharmacology comparison can confirm identity and purity per molecule before treating any pair as comparable.
- Why is the CAS shown as 'verify per COA' for Mazdutide?
- Mazdutide is still investigational, and the salt / counter-ion form and exact lipidation can vary across sources, so the catalog CAS (2259884-03-0) is best treated as a starting reference to be confirmed against the lot COA. Peptuno confirms identity by ESI-MS against the theoretical mass for the supplied form and reproduces that value on the COA for direct citation.
- Should a lab source Mazdutide or Survodutide for GLP-1 / glucagon dual-agonist work?
- Both target the same receptor pair (GLP-1R + GCGR, no GIP), so the choice is a documentation question rather than a mechanism one: align the reference standard to the clinical-data set the work cites. The two differ in peptide sequence and lipidation chemistry — confirm exact identity per batch COA before treating them as interchangeable in any comparison.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.
Related products
Survodutide
GLP-1 / glucagon dual agonist · metabolic research peptide (BI 456906)
Retatrutide
GIP / GLP-1 / glucagon tri-agonist · 39-mer metabolic research peptide
Tirzepatide
GIP / GLP-1 dual receptor agonist · 39-mer metabolic research peptide